About NephroDI Therapeutics
NephroDI Therapeutics is a private company based in Seattle, Washington. It has reported $3,600,018 raised in two offerings on Form D since February 2021.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 11, 2024 | Jun 18, 2024 | $2,000,000of $3.9M target | 2 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Feb 11, 2021 | Feb 23, 2021 | $1,600,018fully sold | 1 | $1.6M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $3,600,018 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on NephroDI Therapeutics's Form D filed Jun 18, 2024.
RH
Rachael Hagan
President and director
MG
Michael Grissinger
Director
BM
Bibhash Mukhopadhyay
Director
JD
Jeff Sands, M.D.
Executive officer
Earlier filings also listed Fred Callori (director, last listed Feb 2021), Donna See (director, last listed Feb 2021) and Chris Garabedian (director, last listed Feb 2021).